Curis, Inc. (CRIS) and Debiopharm Announce Initiation of Phase I-II Clinical Study of HSP90 Inhibitor Debio 0932
8/15/2012 9:24:14 AM
LEXINGTON, Mass. and LAUSANNE, Switzerland, Aug. 15, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, and Debiopharm Group (Debiopharm), a group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that Debiopharm has begun treating patients in its HALO Phase I/II clinical trial of orally-administered Heat Shock Protein 90 (HSP90) inhibitor Debio 0932 in combination with chemotherapy regimens in patients with advanced stages of non-small cell lung cancer (NSCLC).
comments powered by